This category links to companies actively involved in research and development of their potential therapeutic products, derived from biological rather than chemical synthesis.
Receptor-based drug discovery in the fields of diabetes, obesity, cardiovascular, sleep disorders, neurodegeneration, schizophrenia, depression and anxiety. Profile of company in San Diego, California. (Nasdaq: ARNA)
Development and marketing of products to treat viral infections, cancer and autoimmune diseases. Features product pipeline and company details. Frankfurt, Germany.
Developing small molecule and peptide drugs in regulatory signaling and regenerative pathways. Introduces technical background, product pipeline, collaborations, investment data and careers headquartered from Cambridge, Massachusetts. (Nasdaq: CVGP)
Identifies and characterises structural variants of polyketides and non-ribosomal cyclic heptapeptides from cyanobacteria, and optimises pharmacological activity using biocombinatorial techniques. Profile, collaborators and contacts in Germany.
Development, production, and marketing of human therapeutics. Includes research history, product pipeline, global corporate and career information. San Francisco, California.
Researching nuclear receptors and gene deregulation for treatment of cardiovascular, metabolic and inflammatory diseases. Includes information about genomic research headquartered in Loos, France.
Researches and develops growth factor blockers and anti-cancer vaccines. Includes clinical programs, investor details and overview of company in New York City. (Nasdaq: IMCL)
Developing novel drugs against targets inside nerve cells to treat CNS disorders. Includes therapeutic projects, target biochemistry, corporate data and contacts for headquarters in New York City.
Developing drugs and therapies to reverse the effects of human aging by focusing on preserving the length of telomeres, to keep them more resilient. Careers in Reno, Nevada.
Development and manufacture of recombinant proteins and peptides, in partnership with big pharmas. Includes licensing of technology derived from the host-defense protein BPI, monoclonal antibodies to treat chemotherapy-induced thrombocytopenia, and to target cancer. Based in Berkeley, California.
Developing a pulmonary insulin delivery system, and immunotherapy of cancer, by identifying tumor-related antigens, DNA and peptide-based drugs evoking cell-mediated responses. Located in Valencia, California.
Develops and commercializes vaccines, and novel antiviral therapeutics for category A pathogens, infectious diseases, and potential bio-defense. Laboratories in Corvallis, Oregon, headquartered in New York City. (Nasdaq: SIGA)